World Orphan Drugs EU 2021

Featuring contributions from Syneos Health experts across the clinical-commercial spectrum, this book offers unique insights from various perspectives, including third-party capital providers, caregivers, patient advocacy groups, drug development professionals, marketing and commercial experts, and patients.

Supporting Rare Disease Drug Development in the COVID-19 Era and Beyond

16th November 14:10 CET
 

Speaker:

Juliet Hulse

Senior Director, Global RN Strategy and Patient Advocacy, Illingworth Research Group™

• Joined Illingworth in 2011, with 4  years as a senior manager having supported the global expansion of Illingworth and project managed and led nursing research teams internationally in a variety of therapeutic areas
• Over 20 years’ experience within clinical research, commencing her career in cardiology research covering multiple Phase I- IV trials. Juliet more recently specialised in neurology research, in particular the field of multiple sclerosis.
• Wide experience in the management of trial projects from initiation to close out as well as working with site investigators to improve patient recruitment and patient retention to the study protocols. She believes developing a strategy that places the patient in the centre of the trial is vital for a successful study.
• Expertise in driving patient centric initiatives into the strategic planning and operational aspects of decentralized studies.

Quality-By-Design: Strategies for Successful Long-Term Follow Up Studies in Cell and Gene Therapies

16th November 15.40 CET

Speaker:

Noolie Gregory

VP, DCT Operations Cell & Gene Therapy, Syneos Health

Noolie leads the team in charge of thoughtful and appropriate application and implementation of Decentralized Clinical Trials (DCT). Noolie bring 15+ years of experience in medical affairs at a top pharmaceutical company and subject matter expertise in real world and late phase research. Noolie is also a member of the Decentralized Trials & Research Alliance work streams helping shape industry thinking around the DCT approaches.

Don’t miss your chance to win a copy of our new book:

Rare Disease Drug Development: Clinical, Scientific, Patient and Caregiver Perspectives.

Simply go to the Syneos Health booth at the World Orphan Drug Conference and enter your name to win!

Syneos Health Additional Resources:

• Rare Disease Day Symposium 2021: Harnessing the Power Of Community
• Rare Disease Drug Development: Innovation Perspectives
• Rare Disease Day Video
• Fireside Chat on Rare Diseases: Listening to Patients and Advocacy Groups
• Challenges and Opportunities in Epilepsy Clinical Trials
• Innovation perspectives in Rare Disease Drug Development
• The Critical Success Factor for Fully Realizing Benefits of Decentralized Trials 
• Decentralized Solutions from Syneos Health

Register Now